Dr. Sandler Discusses Hypofractionation in Prostate Cancer

Howard M. Sandler, MD
Published: Wednesday, Mar 07, 2018



Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

One of the major trends in radiation oncology for prostate cancer is hypofractionation, says Sandler. In the past, radiation oncologists would typically give up to 45 treatments, which is about 9 weeks of therapy. Hypofractionation uses fewer radiation fractions, says Sandler, and studies published in 2016 and 2017 showed that dramatically shorter regimens could produce similar outcomes.

The 2 regimens that have been studied are a 20-fraction regimen and a 28-fraction regimen. These regimens were shown to be noninferior to standard fractionation without increasing side effects, which has led to widespread adoption of these shorter regimens. Sandler says that guidelines are currently being finalized for the use of hypofractionation in prostate cancer.
SELECTED
LANGUAGE


Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

One of the major trends in radiation oncology for prostate cancer is hypofractionation, says Sandler. In the past, radiation oncologists would typically give up to 45 treatments, which is about 9 weeks of therapy. Hypofractionation uses fewer radiation fractions, says Sandler, and studies published in 2016 and 2017 showed that dramatically shorter regimens could produce similar outcomes.

The 2 regimens that have been studied are a 20-fraction regimen and a 28-fraction regimen. These regimens were shown to be noninferior to standard fractionation without increasing side effects, which has led to widespread adoption of these shorter regimens. Sandler says that guidelines are currently being finalized for the use of hypofractionation in prostate cancer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x